Eli Lilly's first quarter 2026 revenue surged 56% on GLP-1 drug sales, leading to a raised full-year outlook.

Eli Lilly reported first-quarter revenue of $19.8 billion, a 56% increase year-over-year, with non-GAAP EPS growing 156% to $8.55. These results were driven by substantial volume growth in its key GLP-1 medicines, leading the company to raise its full-year 2026 financial guidance.

Key Highlights

• Worldwide revenue grew 56% to $19.8 billion, driven by a 65% increase in volume, partially offset by a 13% decrease from lower realized prices.
• Combined sales of GLP-1 drugs Mounjaro and Zepbound reached $12.8 billion for the quarter, with Mounjaro sales growing 125% to $8.7 billion and Zepbound sales growing 80% to $4.2 billion.
• The company increased its full-year 2026 revenue guidance by $2 billion to a new range of $82.0 to $85.0 billion and raised its non-GAAP EPS guidance to a range of $35.50 to $37.00.